Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
95 hedge funds and large institutions have $838M invested in Dicerna Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
48% more capital invested
Capital invested by funds: $565M → $838M (+$273M)
12% more funds holding
Funds holding: 85 → 95 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
+$33.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$16.8M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.2M |
| 4 |
Goldman Sachs
New York
|
+$11.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.84M |
| 2 |
EU
Emory University
Atlanta,
Georgia
|
-$2.2M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.48M |
| 4 |
SIM
Spark Investment Management
New York
|
-$1.23M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.22M |
DRNA Hedge Fund Activity: Q3 2018 in Review
95 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q3 2018, worth a combined $838M — up 48% from $565M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new DRNA positions and 10 closed out — a net gain of 10 holders — while 37 added to existing stakes and 20 trimmed.
The largest buyer was Bridger Management, adding an estimated $33.5M. The largest seller was Fidelity Investments, cutting an estimated $4.84M.
- 95 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q3 2018, up from 85 in Q2 2018.
- Funds reported $838M of Dicerna Pharmaceuticals, Inc. stock for Q3 2018, up 48% quarter-over-quarter.
- 20 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q3 2018 and 10 closed out, a net change of +10 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q3 2018 was Bridger Management, an estimated $33.5M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q3 2018 was Fidelity Investments, an estimated $4.84M sold.
Based on aggregated 13F filings for Q3 2018.